新型冠状病毒肺炎患者淋巴细胞亚群计数的Meta 分析。
Lymphocyte Subset Counts in COVID-19 Patients: A Meta-Analysis.
机构信息
BD Biosciences, San Jose, California, USA.
BD Global Clinical Development, Franklin Lakes, New Jersey, USA.
出版信息
Cytometry A. 2020 Aug;97(8):772-776. doi: 10.1002/cyto.a.24172. Epub 2020 Jul 18.
Abstract
A reduced peripheral blood absolute lymphocyte count with an elevated neutrophil count has been a consistent observation in hospitalized coronavirus disease 2019 (COVID-19) patients. In this brief meta-analysis, the reduction of lymphocyte subset counts in COVID-19 patients was investigated across 20 peer-reviewed studies meeting criteria for reporting lymphocyte subset counts and COVID-19 disease severity. CD4+ T cell, CD8+ T cell, B cell, NK cell, and total lymphocyte cell counts all showed statistically significant reduction in patients with severe/critical COVID-19 disease compared to mild/moderate disease. T-cell subsets showed the largest standardized magnitude of change. In some studies, multivariate analysis has shown that CD4 and/or CD8 T-cells counts are independently predictive of patient outcomes. © 2020 International Society for Advancement of Cytometry.
摘要
在住院的 2019 冠状病毒病（COVID-19）患者中，外周血绝对淋巴细胞计数减少伴中性粒细胞计数升高是一个一致的观察结果。在这项简短的荟萃分析中，对符合报告淋巴细胞亚群计数和 COVID-19 疾病严重程度标准的 20 项同行评审研究中 COVID-19 患者的淋巴细胞亚群计数减少进行了调查。与轻度/中度疾病相比，严重/危重症 COVID-19 患者的 CD4+T 细胞、CD8+T 细胞、B 细胞、NK 细胞和总淋巴细胞计数均显示出统计学显著降低。T 细胞亚群显示出最大的标准化变化幅度。在一些研究中，多变量分析表明 CD4 和/或 CD8 T 细胞计数是患者预后的独立预测因素。©2020 国际细胞分析学会。
相似文献
1
Lymphocyte Subset Counts in COVID-19 Patients: A Meta-Analysis.
Cytometry A. 2020 Aug;97(8):772-776. doi: 10.1002/cyto.a.24172. Epub 2020 Jul 18.
2
Lymphocyte subsets with the lowest decline at baseline and the slow lowest rise during recovery in COVID-19 critical illness patients with diabetes mellitus.
Diabetes Res Clin Pract. 2020 Sep;167:108341. doi: 10.1016/j.diabres.2020.108341. Epub 2020 Jul 22.
3
Apoptosis and immunophenotyping of peripheral blood lymphocytes in Iranian COVID-19 patients: Clinical and laboratory characteristics.
J Med Virol. 2021 Mar;93(3):1589-1598. doi: 10.1002/jmv.26505. Epub 2020 Sep 28.
4
T-Cell Subset Counts in Peripheral Blood Can Be Used as Discriminatory Biomarkers for Diagnosis and Severity Prediction of Coronavirus Disease 2019.
J Infect Dis. 2020 Jun 29;222(2):198-202. doi: 10.1093/infdis/jiaa252.
5
Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients.
EBioMedicine. 2020 May;55:102763. doi: 10.1016/j.ebiom.2020.102763. Epub 2020 Apr 18.
6
Immune dysfunction following COVID-19, especially in severe patients.
Sci Rep. 2020 Sep 28;10(1):15838. doi: 10.1038/s41598-020-72718-9.
7
The role of cytokine profile and lymphocyte subsets in the severity of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.
Life Sci. 2020 Oct 1;258:118167. doi: 10.1016/j.lfs.2020.118167. Epub 2020 Jul 29.
8
Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19.
J Infect. 2020 Aug;81(2):318-356. doi: 10.1016/j.jinf.2020.03.054. Epub 2020 Apr 11.
9
Elevated Exhaustion Levels of NK and CD8 T Cells as Indicators for Progression and Prognosis of COVID-19 Disease.
Front Immunol. 2020 Oct 14;11:580237. doi: 10.3389/fimmu.2020.580237. eCollection 2020.
10
Effects of Short-Term Low-Dose Glucocorticoids for Patients with Mild COVID-19.
Biomed Res Int. 2020 Sep 23;2020:2854186. doi: 10.1155/2020/2854186. eCollection 2020.
引用本文的文献
1
Pathogen distribution and prognostic risk factors in respiratory intensive care unit (RICU) patients of a large general hospital before and after COVID-19 pandemic.
J Thorac Dis. 2025 Aug 31;17(8):6176-6188. doi: 10.21037/jtd-2025-1296. Epub 2025 Aug 27.
2
Difference in Lymphocyte Subset Counts According to Disease Severity and SARS-CoV-2 Variants of Hospitalized COVID-19 Patients in Korea.
J Korean Med Sci. 2025 Jul 28;40(29):e172. doi: 10.3346/jkms.2025.40.e172.
3
Steroid Pulse Therapy Leads to Secondary Infections and Poor Outcomes in Patients with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Intensive Care Units: A Retrospective Cohort Study.
Viruses. 2025 Jun 6;17(6):822. doi: 10.3390/v17060822.
4
The subsets of blood circulating T-cells associated with the development and prognosis of coinfection in patients with critical COVID-19.
Front Immunol. 2025 May 9;16:1586302. doi: 10.3389/fimmu.2025.1586302. eCollection 2025.
5
Efficient and scalable construction of clinical variable networks for complex diseases with RAMEN.
Cell Rep Methods. 2025 Apr 21;5(4):101022. doi: 10.1016/j.crmeth.2025.101022. Epub 2025 Apr 10.
6
Early lymphopenia as a predictor of COVID-19 outcomes: A multicenter cohort study.
Acute Med Surg. 2025 Mar 21;12(1):e70044. doi: 10.1002/ams2.70044. eCollection 2025 Jan-Dec.
7
Automated cytometric gating with human-level performance using bivariate segmentation.
Nat Commun. 2025 Feb 12;16(1):1576. doi: 10.1038/s41467-025-56622-2.
8
A Review of the Hematological Picture of Severe COVID-19 Infection.
Cureus. 2025 Feb 9;17(2):e78797. doi: 10.7759/cureus.78797. eCollection 2025 Feb.
9
Prospective and Longitudinal Analysis of Lymphocyte Subpopulations in SARS-CoV-2 Positive and Negative Pneumonia: Potential Role of Decreased Naïve CD8 in COVID-19 Patients.
Viruses. 2024 Dec 30;17(1):41. doi: 10.3390/v17010041.
10
Sustained Vascular Inflammatory Effects of SARS-CoV-2 Spike Protein on Human Endothelial Cells.
Inflammation. 2024 Dec 31. doi: 10.1007/s10753-024-02208-x.
本文引用的文献
1
Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis.
J Intensive Care. 2020 May 24;8:36. doi: 10.1186/s40560-020-00453-4. eCollection 2020.
2
The role of biomarkers in diagnosis of COVID-19 - A systematic review.
Life Sci. 2020 Aug 1;254:117788. doi: 10.1016/j.lfs.2020.117788. Epub 2020 May 13.
3
The association of low serum albumin level with severe COVID-19: a systematic review and meta-analysis.
Crit Care. 2020 May 26;24(1):255. doi: 10.1186/s13054-020-02995-3.
4
Characteristics and prognostic factors of disease severity in patients with COVID-19: The Beijing experience.
J Autoimmun. 2020 Aug;112:102473. doi: 10.1016/j.jaut.2020.102473. Epub 2020 Apr 24.
5
Viral and host factors related to the clinical outcome of COVID-19.
Nature. 2020 Jul;583(7816):437-440. doi: 10.1038/s41586-020-2355-0. Epub 2020 May 20.
6
Clinical and pathological investigation of patients with severe COVID-19.
JCI Insight. 2020 Jun 18;5(12):138070. doi: 10.1172/jci.insight.138070.
7
Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19).
Front Immunol. 2020 May 1;11:827. doi: 10.3389/fimmu.2020.00827. eCollection 2020.
8
A retrospective study on the epidemiological characteristics and establishment of an early warning system of severe COVID-19 patients.
J Med Virol. 2020 Oct;92(10):2173-2180. doi: 10.1002/jmv.26022. Epub 2020 Jun 2.
9
Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression.
J Renin Angiotensin Aldosterone Syst. 2020 Apr-Jun;21(2):1470320320926899. doi: 10.1177/1470320320926899.
10
Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China.
J Allergy Clin Immunol. 2020 Jul;146(1):89-100. doi: 10.1016/j.jaci.2020.05.003. Epub 2020 May 11.
Zotero 插件